Literature DB >> 12843795

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.

Mark E Dudley1, John R Wunderlich, Thomas E Shelton, Jos Even, Steven A Rosenberg.   

Abstract

The generation of T lymphocytes with specific reactivity against tumor antigens is a prerequisite for effective adoptive transfer therapies. Melanoma-specific lymphocyte cultures can be established from tumor infiltrating lymphocytes (TILs) by in vitro culture in high levels of IL-2. We have optimized methods for generating melanoma-reactive TIL cultures from small resected tumor specimens. We report a retrospective analysis of 860 attempted TIL cultures from 90 sequential melanoma biopsy specimens from 62 HLA-A2+ patients. Multiple independent TIL derived from a single tumor often exhibited substantial functional and phenotypic variation. Tumor specific activity was detected in TIL from 29 (81%) of 36 patients screened. TIL cultures selected for high activity were generally capable of large numerical expansion using a single round of a rapid expansion protocol. Limited clonal T-cell populations in an oligoclonal TIL culture could confer specific tumor recognition in these highly selected, highly expanded TIL cultures. These methods were efficient at generating TILs suitable for adoptive transfer therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843795      PMCID: PMC2305721          DOI: 10.1097/00002371-200307000-00005

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  16 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.

Authors:  J L Chen; P R Dunbar; U Gileadi; E Jäger; S Gnjatic; Y Nagata; E Stockert; D L Panicali; Y T Chen; A Knuth; L J Old; V Cerundolo
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

3.  Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.

Authors:  Simone Seiter; Vladia Monsurro; Mai-Britt Nielsen; Ena Wang; Maurizio Provenzano; John R Wunderlich; Steven A Rosenberg; Francesco M Marincola
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

4.  A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard M Sherry; Francesco M Marincola; Susan F Leitman; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Azam Nahvi; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

5.  The extent of the human germline T-cell receptor V beta gene segment repertoire.

Authors:  S Wei; P Charmley; M A Robinson; P Concannon
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

6.  Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.

Authors:  M E Dudley; J Wunderlich; M I Nishimura; D Yu; J C Yang; S L Topalian; D J Schwartzentruber; P Hwu; F M Marincola; R Sherry; S F Leitman; S A Rosenberg
Journal:  J Immunother       Date:  2001 Jul-Aug       Impact factor: 4.456

7.  Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution.

Authors:  S Bownds; P Tong-On; S A Rosenberg; M Parkhurst
Journal:  J Immunother       Date:  2001 Jan-Feb       Impact factor: 4.456

8.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

9.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

Authors:  S R Riddell; K S Watanabe; J M Goodrich; C R Li; M E Agha; P D Greenberg
Journal:  Science       Date:  1992-07-10       Impact factor: 47.728

10.  Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2).

Authors:  M R Parkhurst; E B Fitzgerald; S Southwood; A Sette; S A Rosenberg; Y Kawakami
Journal:  Cancer Res       Date:  1998-11-01       Impact factor: 12.701

View more
  274 in total

1.  Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.

Authors:  Richard W Joseph; Vijay R Peddareddigari; Ping Liu; Priscilla W Miller; Willem W Overwijk; Nebiyou B Bekele; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Victor G Prieto; John D McMannis; Nicholas Papadopoulos; Kevin Kim; Jade Homsi; Agop Bedikian; Wen-Jen Hwu; Patrick Hwu; Laszlo G Radvanyi
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Development of effective immunotherapy for the treatment of patients with cancer.

Authors:  Steven A Rosenberg
Journal:  J Am Coll Surg       Date:  2004-05       Impact factor: 6.113

Review 3.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

4.  Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma.

Authors:  Maria Muccioli; Caitlin Longstaff; Fabian Benencia
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

5.  Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.

Authors:  Luke D Rothermel; Arvind C Sabesan; Daniel J Stephens; Smita S Chandran; Biman C Paria; Abhishek K Srivastava; Robert Somerville; John R Wunderlich; Chyi-Chia R Lee; Liqiang Xi; Trinh H Pham; Mark Raffeld; Parthav Jailwala; Manjula Kasoji; Udai S Kammula
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

Review 6.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

8.  Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies.

Authors:  Mariana Rodríguez Zubieta; David Furman; Marcela Barrio; Alicia Inés Bravo; Enzo Domenichini; José Mordoh
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

9.  Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.

Authors:  Simon Turcotte; Alena Gros; Eric Tran; Chyi-Chia R Lee; John R Wunderlich; Paul F Robbins; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

10.  CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

Authors:  Qunrui Ye; De-Gang Song; Mathilde Poussin; Tori Yamamoto; Andrew Best; Chunsheng Li; George Coukos; Daniel J Powell
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.